Orphazyme A/S
(NASDAQ : ORPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.36%162.970.7%$1035.74m
MRKMerck & Co., Inc. -0.09%77.160.7%$986.69m
LLYEli Lilly & Co. -1.06%219.861.1%$902.68m
PFEPfizer Inc. -1.46%38.910.9%$888.18m
ABBVAbbVie, Inc. -1.18%113.541.9%$724.55m
BMYBristol-Myers Squibb Co. -0.30%66.571.0%$620.59m
AZNAstraZeneca Plc -0.57%58.021.2%$395.33m
OGN -3.50%30.360.0%$316.76m
ANVSAnnovis Bio, Inc. -0.06%90.000.0%$306.24m
NVSNovartis AG -0.86%93.340.2%$180.30m
GSKGlaxoSmithKline Plc -1.45%39.980.2%$150.00m
NOVNNovan, Inc. 1.38%11.005.8%$141.82m
ORPHOrphazyme A/S -50.07%7.270.0%$118.06m
CNSTConstellation Pharmaceuticals, Inc. -0.19%33.760.0%$104.65m
BTXBrooklyn ImmunoTherapeutics, Inc. 7.30%16.4612.4%$101.91m

Company Profile

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.